My HPRA: Register

BCR-ABL tyrosine inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) - Important Safety Information from Novartis, Pfizer, BMS and Ariad as approved by the HPRA

Notice type: 3rd Party Publications

Date: 05/04/2016

  

Problem Or Issue:
Important Safety Information communication from Novartis, Pfizer, BMS and Ariad: BCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) - Need to screen patients for hepatitis B virus before treatment due to risk of hepatitis B reactivation  

Important Safety Information - BCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib)
 

« Back